Systematic Review and Meta-Analysis of Multaq® for Safety in Atrial Fibrillation

Sanofi

Status: Completed

Conditions: Atrial Fibrillation

Treatments: Drug: sotalol; Drug: dronedarone

Study type: Observational

Funder types: Industry

Identifiers

NCT05279833

CSA0010

Details and patient eligibility

About

A systematic literature review (SLR) will be conducted to understand the landscape of evidence on the relative safety and effectiveness/efficacy of dronedarone compared to sotalol in patients with AFib within interventional clinical trials and observational studies.

Enrollment: 87,810 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Following eligibility criteria are defined to select relevant studies from the literature

• Adults with Atrial Fibrillation(AFib) (non-permanent, including paroxysmal or persistent, long-standing persistent AFib [over 12 months]))
• Participants have received either Dronedarone or Sotalol
• controlled clinical trials or comparative observational studies( prospective/retrospective cohort, case-control studies, population-based studies or registry based studies

Exclusion criteria

Exclusion criteria for potential participants are:

• Children/adolescents
• Permanent atrial fibrillation (AFib)